Replies to post #122 on Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

Unlikely, as most aren't ''stem like.'' Now during manufacturing of the ADP-A2M4CD8 product they add an ATKi. This increases the percentage of CD8+ T-cells of the naive and central memory phenotype. It also improves antigen-specific killing and effector functions.

The first registration directed trial (in gastroesophageal) will be underway next year.

Exploring the use of other small molecule inhibitors could help as well https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543